Aatmaj Healthcare H1 FY27 Revenue Rises 54% Amid Expansion

H1 FY27 results were approved on 29 October

Aatmaj Healthcare Ltd reported its H1 FY27 financial results on 29 October 2026 after its board met to approve the half-year numbers. The reported results cover the March-September 2026 period. Total revenue was reported at ₹17.39 crore, including other income, while revenue from operations stood at ₹16.96 crore. Revenue from operations rose 54% from ₹10.81 crore in H1 FY26. However, profit after tax fell to ₹0.37 crore from ₹0.51 crore a year earlier. The company said expansion-related costs, higher operating expenditure and the ramp-up of new specialties affected the conversion of revenue growth into profit.

Revenue growth was led by hospital operations

The company’s investor presentation attributed the growth in revenue to stronger inpatient activity, higher surgical volumes, better occupancy and specialty-care services. The reported revenue from operations figure was ₹1,695.98 lakh for H1 FY27, compared with ₹1,081.04 lakh in H1 FY26. Other income took total revenue to ₹1,738.52 lakh, or ₹17.39 crore. The growth rate indicates a substantial increase in hospital operating activity over the comparable half year. Aatmaj Healthcare’s reported H1 FY27 numbers were unaudited and carried a clean limited review. No earnings-call transcript for the quarter was available in the provided information.

Profit declined despite higher revenue

Profit after tax for H1 FY27 was ₹36.95 lakh, compared with ₹51.07 lakh in H1 FY26. This represents a year-on-year decline of about 27.6% based on the two reported figures. A separate results update described net profit as approximately ₹0.4 crore and down 20% year-on-year. The company’s presentation specifically cited expansion costs, increased operating expenses and the early-stage ramp-up of new specialties as reasons profit did not rise in line with revenue. Basic and diluted earnings per share were ₹0.16, against ₹0.23 in the previous-year period. The figures show that growth in operations came with a near-term cost burden.

Key H1 FY27 financial figures

Anand Hospital integration adds revenue potential

Aatmaj Healthcare said it has fully integrated Anand Hospital along with its laboratory and pharmacy network. The company expects the integrated business to generate annual revenue of ₹9 crore to ₹10 crore and profit before tax and depreciation of ₹1.5 crore to ₹2 crore in FY27. Against stated trailing-12-month revenue of ₹44 crore, the expected revenue contribution represents potential incremental top-line capacity of roughly 20% to 23%. The laboratory and retail pharmacy network are relevant because they add services beyond inpatient hospital care. The integration is part of the company’s broader effort to expand its operating platform. The provided material did not specify the purchase consideration or integration timeline.

New specialties and capacity additions continue

The company commissioned a Cardiothoracic and Vascular Surgery department at Jupiter Hospital in Vadodara during H1 FY27. It also added IVF facilities and expanded adult and neonatal intensive-care capacity. These projects broaden the range of specialty services offered by the hospital network. Such capacity additions can require upfront spending on equipment, staffing and operations before reaching higher utilisation. This context aligns with management’s explanation for the weaker profit conversion during the half year. The company said EBITDA margins are expected to improve as new operational units reach optimal bed occupancy.

PM-JAY empanelment broadens Badnawar access

JTP SP Hospital in Badnawar secured PM-JAY empanelment across five clusters, according to the investor presentation. PM-JAY is a government health assurance programme, and empanelment enables a hospital to serve eligible beneficiaries under the scheme. The filing did not provide expected revenue from the empanelment. Still, the development expands the hospital’s access across the stated clusters. It also places the Badnawar unit alongside the company’s other operational expansion initiatives. The financial effect will depend on patient volumes, service mix and utilisation, none of which were quantified in the available material.

H2 outlook points to continuing growth

Aatmaj Healthcare’s investor presentation indicated expected revenue growth of about 40% for H2 FY27. It also projected that annual PAT could rise by approximately 80% compared with the previous financial year. These are expectations cited in the presentation rather than an earnings-call transcript. The stated margin outlook depends on newer units reaching optimal occupancy levels. Investors will therefore track whether the newer specialty departments, hospital integration and added capacity translate into higher utilisation. The company’s debt-equity ratio was reported at 0.45, with the presentation also referring to strong coverage ratios.

Earlier results provide operating context

For FY26, Aatmaj Healthcare reported revenue from operations of ₹24.32 crore and total income of ₹25.27 crore. Reported PAT for that year was ₹0.71 crore, compared with ₹0.64 crore in FY25. The earlier half-year data show revenue from operations of ₹10.81 crore in September 2025 and ₹8.51 crore in September 2024. The H1 FY27 operational revenue of ₹16.96 crore is therefore well above the corresponding prior periods. But the latest half-year PAT remains below the ₹0.51 crore reported in H1 FY26. The contrast highlights the importance of cost control and occupancy improvement as the company expands.

What investors will monitor next

The central feature of Aatmaj Healthcare’s H1 FY27 update is strong revenue growth alongside lower reported profit. Anand Hospital’s integration, PM-JAY empanelment at Badnawar and newly commissioned specialties are the major operational developments disclosed by the company. Their contribution will be assessed through subsequent revenue, occupancy and margin disclosures. The company has indicated approximately 40% H2 revenue growth and an approximate 80% increase in annual PAT versus the previous financial year. Its next reported results will provide the clearest update on whether these stated targets and the margin improvement outlook are being achieved.